APR Distinguished Lecturer Charles G. Helmick III, MD, provided a look a public health and why it’s important — and why arthritis and other rheumatologic conditions are public health issues.
Three scleroderma experts will outline approaches to scleroderma skin involvement, interstitial lung disease, and pulmonary hypertension during the Wednesday Clinical Practice session, Scleroderma Treatment 2019.
The registry is a rich, best-in-class resource developed by the American College of Rheumatology, and is the first and largest national EHR-enabled rheumatology registry in the United States.
New findings open up the potential for new therapies for autoimmune and inflammatory diseases, such as RA, that target these new functions of complement.
Tuesday will see the ACR’s first-ever session on histiocytic disorders, which have traditionally been seen as rare, obscure, and without good treatment options.
On Saturday, the ACR Board of Directors met to discuss current and future initiatives that impact the ACR’s diverse membership and advance rheumatology.
Both presenters for the ACR: Year in Review agreed that 2019 was a year where the field of rheumatology exploded, both in clinical updates and basic science research, as more people enter the field and technology helps harness “big data.”
The session focused on the clinical manifestations of irAEs associated with cancer immunotherapies, including the molecular pathogenesis, tools that aid early diagnosis and treatment, and shared mechanisms and relationships with primary autoimmune diseases.
The risks and benefits of vaccinations for common infectious diseases as well as strategies to risk-stratify patients for PJP and recommend appropriate therapy were reviewed.
“Historically, we’ve thought about how we better treat (lupus), how we make patients feel better … But if we want to eliminate lupus, we need to understand early events and how we can stop things before it’s too late,” said Judith James, MD, PhD.